Loading
A phase 3 trial of etoposide, carboplatin and cisplatin in lung cancer, run by Sun Yat-sen University, now recruiting.
Omitting CTV for Primary Tumor in LS-SCLC is a phase 3, randomised interventional study registered as NCT07008716 by Sun Yat-sen University, with a registry enrolment figure of 852 participants, started 2025-06-03 and due to reach its primary completion in 2027-12-31. Interventions recorded: Radiation Therapy; Etoposide + carboplatin; Etoposide + cisplatin; Creating CTV for primary tumor; prophylactic cranial irradiation (PCI). Conditions listed: SCLC, Limited Stage; Radiation Exposure; Radiotherapy Side Effect; Progression. Primary outcome: Local progression free survival; Severe toxicity free survival. Lung eligibility wording from the registry: "Small cell lung cancer confirmed by histology or cytology; TNM stage IA-IIIC (AJCC 8th edition, 2017; limited-stage) without intrapulmonary metastasis;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Limited-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot), Cisplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents, Carboplatin and the tag lung-deep-dive.